

# **Recombinant Human DDR1-Fc Protein**

Catalog Number: P1024

## DESCRIPTION

Catalog Number/Size P1024-100: 100 μg

> P1024-200: 200 μg P1024-500 500 μg

Source Human DDR1 (Accession\*AQY76781) extracellular domain (Asp21-Ile418) fused with the Fc portion of human IgG1, produced from

HEK293 cells.

Human DDR1 (Asp21-Ile418) GSGGGG Human IgG1 (Asp104-Lys330) Accession#AQY76781

N-terminal C-terminal


Structure Disulfide-linked homodimer

**Predicted Molecular Weight** 70 kDa, at reducing conditions Concentration 1 mg/mL in sterile 1xPBS, pH 6.8

Storage -20°C or below

**Estimated Purity** >95% as determined by SDS-PAGE **Protein Aggregation** <5% as determined by SDS-PAGE

## **SDS-PAGE** Analysis



20 µg/lane of human DDR1Fc Chimera was resolved on SDS-PAGE gel in non-reducing (lane 2) and reducing (lane 3) conditions and visualized by

CoomassieBlue staining.



## **Recombinant Human DDR1-Fc Protein**

Catalog Number: P1024

**Application** Biochemical analysis

Product Description DDR1 (discoidin domain receptor tyrosine kinase 1), also known as CD167, CAK, DDR, NEP, HGK2, PTK3, RTK6, TRKE, EDDR1,

MCK10, NTRK4, and PTK3A,is a receptor tyrosine kinase (RTK) and belongs to a subfamily of tyrosine kinase receptors with a homology region to the Dictyosteliumdiscoideum protein discoidin I in its extracellular domain. DDR1 consists of three regions (an extracellular ligand binding domain, a transmembrane domain, and an intracellular region containing a kinase domain), with its kinase activity induced by receptor-specific ligand binding. Collagen binding to DDR1 stimulates its autophosphorylation, activating kinase activity and signaling to downstream signaling pathways. DDR1 expression is restricted to epithelial cells, particularly in the kidney, lung, gastrointestinal tract, and brain and is significantly over-expressed in several human tumors from breast, ovarian, esophageal, and brain. DDR1 plays a key role in the development and progression of breast and ovarian cancer and is a promising therapeutic target.

References Johnson, J. D., Edman, J. C., Rutter, W. J., Proc. Nat. Acad. Sci. 90: 5677-5681, 1993.

Chen, L., et al, Frontiers in Cell and Dev. Bio.volume 9, article #747314, 2021

Letinger, B., Int Rev Cell Mol Biol., 310: 39-87, 2014

Vogel, W., et al., Mol. Cell, 1: 13-23, 1997